These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21789012)

  • 21. Prostate-specific antigen spikes after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Anderson RL
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):450-6. PubMed ID: 12243821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Cancer J; 2005; 11(3):234-40. PubMed ID: 16053667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
    Papagikos MA; Deguzman AF; Rossi PJ; McCullough DL; Clark PE; Lee WR
    Brachytherapy; 2005; 4(4):252-8. PubMed ID: 16344254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-response analysis of biochemical control outcomes after (125)I monotherapy for patients with favorable-risk prostate cancer.
    Shiraishi Y; Yorozu A; Ohashi T; Toya K; Saito S; Nishiyama T; Yagi Y; Shigematsu N
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1069-75. PubMed ID: 25539368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation.
    Lee LN; Stock RG; Stone NN
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):444-52. PubMed ID: 11872291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 125I brachytherapy for localized prostate cancer: a single institution experience.
    Guarneri A; Botticella A; Filippi AR; Munoz F; Beltramo G; Casetta G; Giglioli FR; Tizzani A; Ragona R; Ricardi U
    Tumori; 2013; 99(1):83-7. PubMed ID: 23549005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dose-response study for I-125 prostate implants.
    Stock RG; Stone NN; Tabert A; Iannuzzi C; DeWyngaert JK
    Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):101-8. PubMed ID: 9588923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose rate brachytherapy of the prostate in elderly patients.
    Chiumento C; Fiorentino A; Caivano R; Clemente S; Fusco V
    Radiol Med; 2013 Dec; 118(8):1412-21. PubMed ID: 22986692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten-year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience.
    Wilson C; Waterhouse D; Lane SE; Haworth A; Stanley J; Shannon T; Joseph D
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):531-8. PubMed ID: 27020620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy.
    Kwok Y; DiBiase SJ; Amin PP; Naslund M; Sklar G; Jacobs SC
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):588-94. PubMed ID: 12062601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.
    Lee LN; Barnswell C; Torre T; Fearn P; Kattan M; Potters L
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):282-9. PubMed ID: 12023131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.
    Takamoto A; Tanimoto R; Bekku K; Araki M; Sadahira T; Wada K; Ebara S; Katayama N; Yanai H; Nasu Y
    Int J Urol; 2018 May; 25(5):507-512. PubMed ID: 29651796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetry doesn't seem to predict the control of organ-confined prostate cancer after I-125 brachytherapy. Evaluation in 150 patients.
    Gastaldi E; Chiono L; Gallo F; Schenone M; Ninotta G; Chiarlone R; Ghiso G; Giberti C
    Arch Ital Urol Androl; 2009 Dec; 81(4):215-7. PubMed ID: 20608144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.